Compugen (NASDAQ:CGEN) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Compugen (NASDAQ:CGEN) issued its earnings results on Tuesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.14), Zacks reports. The company had revenue of $1.47 million during the quarter, compared to analyst estimates of $17.47 million. Compugen had a net margin of 2.67% and a return on equity of 2.62%.

Compugen Stock Up 7.7 %

Shares of CGEN stock opened at $1.81 on Thursday. The company has a market cap of $161.52 million, a P/E ratio of 90.50 and a beta of 2.98. The business has a 50 day moving average of $2.04 and a two-hundred day moving average of $1.84. Compugen has a 52 week low of $1.35 and a 52 week high of $3.03.

Analysts Set New Price Targets

Several brokerages have issued reports on CGEN. Oppenheimer began coverage on Compugen in a research note on Monday, January 13th. They set an “outperform” rating and a $4.00 price objective on the stock. StockNews.com cut Compugen from a “buy” rating to a “hold” rating in a research note on Wednesday.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.